RECRUITINGPhase 2INTERVENTIONAL

Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI

Sodium Glucose Co-Transporter 2 (SGLT2) Inhibition Improves Left Ventricular Function and Reduces Adverse Left-Ventricular Remodeling in High-Risk Patients with Microvascular Obstruction (MVO) Following ST-elevation Myocardial Infarction (STEMI).

About This Trial

The purpose of the research is to determine whether a class of medication called SGLT2 inhibitor will improve the heart's function and reduce its enlargement after a heart attack. Participation in this study will involve taking this class of medication (or a placebo) once daily for six months, one cardiac magnetic resonance imaging (MRI) test during your initial hospitalization, follow-up phone calls at 1 and 3 months, and one cardiac MRI and clinic visit at six months. This is a single center study.

Who May Be Eligible (Plain English)

Who May Qualify: - Patients with their first STEMI (\>18 years) who underwent successful primary PCI and able to give willing to sign a consent form - At least mild LV dysfunction (LVEF \< 50%) on echocardiogram, cMRI or Left Ventriculargram following PCI - Infarct size that is \> 10% of LV mass - The presence of MVO that is \> 10% of infarct size Who Should NOT Join This Trial: - Contraindication to cardiac MRI - Life expectancy \< 1 year - Previous CABG or Valve Surgery - Previous STEMI - Pregnant or planning to become pregnant or lactating women - Cardiogenic shock (not resolved) - Atrial fibrillation or recurrent sustained ventricular arrhythmias (excluding PVCs) - GFR\<30 ml/min/1.73m2 or end-stage renal disease on dialysis - Type 1 diabetes mellitus or history of diabetic ketoacidosis - Type I or II diabetes with insulin use - Prior intolerance of SGLT2 inhibitors - Current use of SGLT2 inhibitors (randomized patients only) - Contraindications to gadolinium Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language

Inclusion Criteria: * Patients with their first STEMI (\>18 years) who underwent successful primary PCI and able to give informed consent * At least mild LV dysfunction (LVEF \< 50%) on echocardiogram, cMRI or Left Ventriculargram following PCI * Infarct size that is \> 10% of LV mass * The presence of MVO that is \> 10% of infarct size Exclusion Criteria: * Contraindication to cardiac MRI * Life expectancy \< 1 year * Previous CABG or Valve Surgery * Previous STEMI * Pregnant or planning to become pregnant or lactating women * Cardiogenic shock (not resolved) * Atrial fibrillation or recurrent sustained ventricular arrhythmias (excluding PVCs) * GFR\<30 ml/min/1.73m2 or end-stage renal disease on dialysis * Type 1 diabetes mellitus or history of diabetic ketoacidosis * Type I or II diabetes with insulin use * Prior intolerance of SGLT2 inhibitors * Current use of SGLT2 inhibitors (randomized patients only) * Contraindications to gadolinium

Treatments Being Tested

DRUG

SGLT-2 inhibitors

SGLT2 inhibitor once daily for six months

DRUG

Placebo

Placebo once daily for six months

Locations (1)

Minneapolis Heart Institute Foundation

Minneapolis, Minnesota, United States